Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XOMA vs KURA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

XOMA Overall Winner 6-Pillar Tally: XOMA 3 – 2 KURA (1 Tie) Matrix Metrics: XOMA 8 – 2 KURA

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas KURA carries 64.1/100 (BUY) at $7.18 (N/M Forward P/E, -394.3% operating margin).

  • Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -394.3% operating margin) and revenue trajectory (-22.6% vs. +10.1% YoY).
  • Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile KURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XOMA vs KURA
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
KURA NASDAQ
Kura Oncology, Inc.
Pharmaceutical Preparations
$7.18
-7.53% 1D
Market Cap $690.9M
TTM Revenue $79M
Forward P/E N/M
Beta / 30D Vol 1.43β · 108% Vol
Unified Composite Score
64.1 / 100 BUY
Tech 63.0 Fund 64.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.2%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $8.86 · SMA50: $10.05

6-Pillar Scorecard Institutional Category Breakdown (XOMA 3 – 2 KURA)

Columns: Metric · XOMA · KURA
1. Valuation Multiples XOMA
Forward P/E 21.5x N/M
Trailing P/E 28.2x N/M
PEG Ratio N/M N/M
EV / Revenue 16.1x 8.3x
2. Growth & Scale KURA
Revenue Growth (YoY) -22.6% +10.1%
Earnings Growth (YoY) +207.9% +0.0%
TTM Revenue (USD) $49M $79M
Market Cap $781.8M $690.9M
3. Profitability & Quality XOMA
Gross Margin 99.0% N/A
Operating Margin -3.9% -394.3%
Net Profit Margin 69.6% 0.0%
Return on Equity (ROE) 34.2% -224.8%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) $8.3M EBITDA -$89M
Cash Flow Margin 17.1% EBITDA Mgn -112.4%
Net Cash / Leverage $7.79 Book/Sh · 34.2% ROE $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KURA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 101.5% (100th %ile) 103.8% (20th %ile)
Put/Call OI Skew N/A 1.50x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XOMA (8) vs KURA (2)
Institutional Metric XOMA KURA Criterion Row Edge
Market Capitalization
Scale
$781.8M $690.9M Larger Scale XOMA
Trailing P/E Ratio
Valuation
28.2x N/M Lower Multiple XOMA
Forward P/E Ratio
Valuation
21.5x N/M Lower Multiple XOMA
Revenue Growth (YoY)
Growth
-22.6% +10.1% Higher Growth KURA
Operating Margin (TTM)
Profitability
-3.9% -394.3% Higher Margin XOMA
Net Profit Margin
Profitability
69.6% 0.0% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
34.2% -224.8% Higher ROE XOMA
52-Week Range Position
Momentum
78% ($22–$45) 6% ($7–$14) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.68β · 37% Vol 1.43β · 108% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD) 64.1 / 100 (BUY) Higher Composite KURA
Trailing 12M Revenue (USD)
Operating Scale
$49M $79M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev N/M PEG · 8.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) -$89M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KURA +29.5 pp
XOMA: -3.81% · KURA: +25.69%
3M Horizon KURA +16.5 pp
XOMA: +9.34% · KURA: +25.84%
6M Horizon XOMA +20.02 pp
XOMA: +34.26% · KURA: +14.24%
1Y Horizon XOMA +22.45 pp
XOMA: +24.6% · KURA: +2.15%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs KURA. Trailing 12-month operating profitability (XOMA -3.9% vs KURA -394.3%) and valuation multiples (XOMA 21.5x vs KURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x
KURA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$79M
Gross MarginN/A
Op. Margin-394.3%
ROE / Fwd P/E-224.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KURA BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 103.8%
IV Percentile 20th %ile
Put/Call OI Skew 1.50x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact KURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $690.9M market capitalization and -394.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XOMA vs KURA Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas KURA carries 64.1/100 (BUY) at $7.18 (N/M Forward P/E, -394.3% operating margin). Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. XOMA 55.8/100 HOLD), XOMA captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-3.9% vs. -394.3% operating margin) and revenue trajectory (-22.6% vs. +10.1% YoY). Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile KURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KURA leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with KURA at +10.1% YoY revenue growth and +0.0% YoY earnings growth on $79M TTM revenue (N/A gross margin, -394.3% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $79M for KURA. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KURA.

XOMA screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas KURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.3x EV/Revenue (-112.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus KURA (-224.8% ROE) capital efficiency.

In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, KURA carries 103.8% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.50x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.43β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.